IL324773A - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- IL324773A IL324773A IL324773A IL32477325A IL324773A IL 324773 A IL324773 A IL 324773A IL 324773 A IL324773 A IL 324773A IL 32477325 A IL32477325 A IL 32477325A IL 324773 A IL324773 A IL 324773A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- microcrystalline cellulose
- dicalcium phosphate
- solid dosage
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23175788 | 2023-05-26 | ||
| PCT/EP2024/064426 WO2024245953A1 (en) | 2023-05-26 | 2024-05-24 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324773A true IL324773A (en) | 2026-01-01 |
Family
ID=86605004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324773A IL324773A (en) | 2023-05-26 | 2024-05-24 | Pharmaceutical compositions |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4719359A1 (es) |
| JP (1) | JP2026518000A (es) |
| KR (1) | KR20260016534A (es) |
| CN (1) | CN121175036A (es) |
| AR (1) | AR132774A1 (es) |
| AU (1) | AU2024279893A1 (es) |
| CL (1) | CL2025003668A1 (es) |
| CO (1) | CO2025018521A2 (es) |
| CR (1) | CR20250538A (es) |
| DO (1) | DOP2025000289A (es) |
| IL (1) | IL324773A (es) |
| MX (1) | MX2025014102A (es) |
| PE (1) | PE20260438A1 (es) |
| TW (1) | TW202510865A (es) |
| WO (1) | WO2024245953A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| WO2022147519A1 (en) * | 2021-01-04 | 2022-07-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of capivasertib and process for preparation thereof |
| CN119278041A (zh) * | 2022-03-31 | 2025-01-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体(egfr)酪氨酸激酶抑制剂 |
-
2024
- 2024-05-24 CR CR20250538A patent/CR20250538A/es unknown
- 2024-05-24 TW TW113119333A patent/TW202510865A/zh unknown
- 2024-05-24 KR KR1020257043170A patent/KR20260016534A/ko active Pending
- 2024-05-24 CN CN202480034498.5A patent/CN121175036A/zh active Pending
- 2024-05-24 PE PE2025002816A patent/PE20260438A1/es unknown
- 2024-05-24 WO PCT/EP2024/064426 patent/WO2024245953A1/en not_active Ceased
- 2024-05-24 JP JP2025568713A patent/JP2026518000A/ja active Pending
- 2024-05-24 AU AU2024279893A patent/AU2024279893A1/en active Pending
- 2024-05-24 IL IL324773A patent/IL324773A/en unknown
- 2024-05-24 AR ARP240101316A patent/AR132774A1/es unknown
- 2024-05-24 EP EP24729794.8A patent/EP4719359A1/en active Pending
-
2025
- 2025-11-21 DO DO2025000289A patent/DOP2025000289A/es unknown
- 2025-11-24 CL CL2025003668A patent/CL2025003668A1/es unknown
- 2025-11-25 MX MX2025014102A patent/MX2025014102A/es unknown
- 2025-12-23 CO CONC2025/0018521A patent/CO2025018521A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025014102A (es) | 2026-01-07 |
| CN121175036A (zh) | 2025-12-19 |
| TW202510865A (zh) | 2025-03-16 |
| CO2025018521A2 (es) | 2026-01-13 |
| PE20260438A1 (es) | 2026-02-19 |
| WO2024245953A1 (en) | 2024-12-05 |
| EP4719359A1 (en) | 2026-04-08 |
| AR132774A1 (es) | 2025-07-30 |
| DOP2025000289A (es) | 2026-01-15 |
| AU2024279893A1 (en) | 2026-01-22 |
| CR20250538A (es) | 2026-04-21 |
| JP2026518000A (ja) | 2026-06-02 |
| KR20260016534A (ko) | 2026-02-03 |
| CL2025003668A1 (es) | 2026-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105025886B (zh) | 地拉罗司(deferasirox)的口服制剂 | |
| CA3073568A1 (en) | High concentration dosage forms of pridopidine | |
| Priyanka et al. | A comprehensive review on pharmaceutical mini tablets | |
| EP2538924B1 (en) | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation | |
| US12453729B2 (en) | Pharmaceutical formulations | |
| Neeharika et al. | Preparation and evaluation of zafirlukast compression coated tablets for chronotherapeutic drug delivery | |
| WO2024245953A1 (en) | Pharmaceutical compositions | |
| CN113811294B (zh) | 用于治疗或预防高血压和高脂血症的单一剂型药物组合物 | |
| BR112020006995A2 (pt) | formas de dosagem de dissuasão de abuso de liberação modificada | |
| Patil et al. | Chronomodulated press-coated pulsatile therapeutic system for aceclofenac: optimization of factors influencing drug release and lag time | |
| Dembla et al. | Formulation development and evaluation of gabapentin controlled release tablets | |
| CN102238944A (zh) | 用于制备生物粘附压制基质的方法 | |
| Akbar et al. | Development and characterization of atorvastatin calcium sustained release tablet using carbomer-974 and hypromellose-15000 cps | |
| Bello | Physiochemical and drug release properties of Liquisolid formulations in comparison to their physical mixture counterparts | |
| Kumar et al. | Design, formulation and evaluation of sustained release bilayer tablets of ciprofloxacin hydrochloride | |
| Purkar et al. | Formulation Development and Evaluation of Quetiapine fumarate Extended-Release tablet by using 2 3 Factorial designs | |
| Singh et al. | Colon specific chronotherapeutic drug delivery for nocturnal asthma: effect of Eudragit enteric coating on matrix tablets of salbutamol sulphate | |
| WO2025265110A1 (en) | Oral pharmaceutical compositions comprising a naphthyridine compound | |
| EA048243B1 (ru) | Фармацевтический состав | |
| Barde et al. | Development and In Vitro Evaluation of Extended Release Matrix Tablet of Metoprolol Succinate | |
| TW202224681A (zh) | 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物 | |
| Rameshgiri | Development and Evaluation of Controlled Release Matrix Tablets of Diltiazem Hydrochloride Using Natural Polymers | |
| WO2021118403A1 (ru) | Система доставки 2-этил-6-метил-3-гидроксипиридина сукцината для перорального применения | |
| Patel | Formulation and evaluation of ranolazine sustained release tablets by hot melt coating technique | |
| Sitarambhai | Formulation and Evaluation of Sustained Release Levofloxacin Matrix Tablets |